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Making DNA and its becoming an experimental commodity
Dominic J. Berry
London School of Economics and Political Science; University of Edinburgh, UK
ABSTRACT
This paper pursues the history of biology and technology in tan-
dem. It focuses on DNA’s materiality regardless of informational
properties. My emphasis on ‘making’ integrates attention to cul-
tures of work in material histories of biology with analyses of the
development of technical apparatuses and machines. When it
comes to the history of DNA synthesis our materials are as much
chemical as they are biological, which means that there is really a
third history present, one that also needs to be drawn in, but on its
own terms. I demonstrate the ways in which different chemistries
have been combined with different technologies, all together
affording different arrangements of personnel and biological
science. It is a history of how synthesised DNA first came to be,
became desired, and became a commodity, available for inclusion
in a wide variety of experiments and experimental systems. This
method could be replicated for other ‘experimental commodities’.
KEYWORDS
Synthetic biology; DNA
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1. Introduction
How has DNA been made, how was it made into an experimental commodity, and why
does this all matter? We can begin, perhaps a little conservatively, by appreciating that how
DNA is made in organisms became a central research question in modern biology
particularly once the significance of these molecules for heredity and development was
recognised.1 It is also true that today virtually everything that goes on in amolecular biology
laboratory (broadly defined) depends on the ability to acquire precisely defined lengths of
DNA, and that annual sales of synthesised DNA run into the hundreds of millions of
dollars. For more than half a century synthesised deoxyribonucleic acid has been both
a target of investigation and a laboratory tool.2 Only some aspects of this history, which
spans the length of the twentieth century into the twenty-first and implicates all corners of
the globe, can be covered here. It is to be hoped that this paper will help inspire a deeper and
more global investigation of DNA synthesis.
In truth ‘DNA synthesis’ is an inadequate term, because this is something that can occur
in a number of different ways, the differences or similarities between which open up ground
for competition as to ‘true’ synthesis, or erase differences that matter fundamentally by
extending the word synthesis beyond its useful bounds. I cannot say ‘non-biological
synthesis’ because the question of what does or does not constitute biology recurs
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throughout. Nor can I say ‘chemical synthesis’, not only because that would beg the same
question as biology, but also because the differences between the kinds of early apparatus
used for these purposes and the eventual technologies that commercialised them for the
consumer cannot be reduced to chemistry alone. And indeed the chemistry by which DNA
is made can itself be different: for that part of the story this is precisely the point. At
a workshop dedicated to the history of DNA synthesis I made use of the term, ‘mechano-
chemical’ to capture the various combinations of instruments and chemical approaches
that can make DNA, but this term received as many furrowed brows as it did wrinkled up
noses.3 For now I shall resort to saying DNA synthesis and allow you to gather the nuances
and differences that this masks as we go.
In carving a space for DNA synthesis I am also creating its broader context, that of the
history of ‘making’ DNA. My interest and focus on making came as a direct result of my
collaboration with social scientists on the Engineering Life project.4 On this side of the
problem, we might worry that referring to all kinds of DNA production as ‘making’ is
inappropriate, perhaps becausemaking demands amaker. Consider the research of persons
such as Arthur Kornberg, whose work determining the conditions necessary to ensure the
successful completion of enzymatic actions that build DNA in a test tube were international
headline-grabbing news.5 Kornberg did not ‘make’ anything, we might argue, rather he
facilitated the translocation of phenomena that typically occur in one place, the cell, to
another, the test tube.6 But this kind of putative distinction is precisely the stuff of history.
That DNA synthesis and its ways of making DNA much more clearly implicated actors
as designer-makers was part of the polemic surrounding these technologies at their origin,
and contributed to inspiring new cultures of biological science and technology. This
influence is today most clearly visible in the community of synthetic biologists, but was
also visible in earlier parts of chemistry, molecular biology, industrial biology, and perhaps
also within other subcultures of biological science. In this article I do not intend to write
a history of synthetic biology or only of synthetic biology. Instead this paper provides the
foundations for a new integrated historiographical approach, one working at a level
removed from the particulars of synthetic biology, but which nevertheless has very direct
implications for synthetic biology and its historians.7 Emphasising that from the outset the
methods of making DNA discussed here were directly associated with notions of design
and deliberateness, I am not saying we need to adopt these valuations and interpretations.
Rather that we need to be alert to them and their history. These kinds of consideration are
all the more urgent in a paper that aims to draw together histories of biology and
technology, in ways that I hope are somewhat novel, but which are also inspired by and
build on a range of historical discussions and models.8
In his path-breaking book The Uses of Life, Robert Bud argued that there is more to
biological technology than biotechnology, the corollary being that biotechnology represents
only one distinct culture of biology and technology together.9 Despite these conclusions
opening up a vast field of view, he is most commonly cited as merely demonstrating that
biotechnology has a long history, which is an unhappily narrow appreciation of his results,
and potentially an incorrect one. I have tried to take The Uses of Life to heart, by allowing
different actors to have their own understanding of how their biological materials are more
or less manufactured, while also imposing my own historiographical category of ‘making’
which will be appealed to throughout. A key pay-off for doing so is that we get to watch as
DNA synthesis eventually does come to be assimilated into ‘biotechnology’, in ways that
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pay no attention to its prehistory, precisely as we would expect in a strict future-oriented
biotechnological mode, but which we would miss if only starting with or looking for
biotech.10 A history of making also allows me to walk through territory often carved up
according to structure and information without allowing either of these terms, or their
combination, to constrain the narrative.11
In Culturing Life Hannah Landecker recognizes actors in the past and present render-
ing their biological materials in technological terms. Her account is of scientific actors
remaking biology as technology. At the same time she emphasises the need for us, as
contemporary analysts, to alienate ourselves from these interpretations, to make them
strange again. Alienation facilitates history-making by resisting the assumptions of actors
as facts of the matter, making it easier to see the social, epistemic and political work that
these characterisations achieved and continue to achieve. I agree with the need to do this,
but I intend to do so symmetrically, with all of the actors and interlocutors who claim to
have things to say on behalf of biology. By contrast, one of Landecker’s strategies is to
counter technological renderings of biology with her own, in which biology’s plasticity
and temporal features are emphasised, so that an alternative biological discourse is made
possible, through life no less. I do not adopt this strategy. The alternative view of biology
that Landecker is putting together would be better looked for within the cast of characters
that my historical work hopes to explore and explain, rather than be included in the
assumptions undergirding this paper. Setting life aside is also a way in which I can make
my history more immediately available to a wider range of philosophers and sociologists
of science, who may find the case useful for discussions of affordance, bio-objects, the
materiality of data practices, biological engineering, integration of the philosophy of
biology and chemistry, or narrative knowledge.12
Angela Creager’s integrative efforts between biology and chemistry have been hugely
important for building the historiographical landscape present in this paper.13 Though she
does not explicitly call for additional integrative work between historians of biology and
technology, this is effectively what she does in some prominent places, as in her chapter on
the development of the ultracentrifuge and its incorporation into experimental systems. In
addition, Creager’s attention to the means and methods of making diverse things also
resonate inmy case. A potential difference between our approaches, though not a hard-and
-fast one, is that I am decidedly warier of the need for informational interpretations of genes
andDNA for the purposes of driving historical accounts forward. I interpret the dominance
of an information framework as having helpedmarginalize the cases discussed here, and no
doubt many other aspects of biological making that have mattered on their own (not-
necessarily informational) terms.
Given all of the overlapping and interrelated biological, technological, chemical and
engineered components that make up a history of DNA synthesis, it has received remark-
ably little historical attention. The work of Har Gobind Khorana is the most thoroughly
explored thus far, but most historians have worked at a conceptual scale where the genetic
‘code’ looms large, leaving much more to be done.14 InMembranes to Molecular Machines
Matthias Grote indeed pushes us further, arguing that the importance of Khorana’s
research has been understood much too narrowly thanks to the existing historiographical
bias towards information and code breaking. Grote also points out that Khorana’s research
interests have typically excluded him from a historiography that has remained focussed on
molecular genetics and metabolic chemistry.15 The informational aspect of the history of
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DNA has been allowed to stand in for too much of this history. At the same time, the many
roles played by DNA synthesis have been underappreciated because historians have
typically treated all the ways of making DNA that emerged in the second half of the
twentieth century as part of an amorphous biotechnological mass. Perhaps they have
ultimately been right to do so- this judgement will always depend on the question being
pursued. My questions were: how can we write histories of biology that keep material-
semiotics and economics close at hand?; How can we create space for engineering – as
a profession, a body of knowledge, an additional or alternative epistemology, etc. and not
just as something appealed to rhetorically – in the history of biology?; How can historio-
graphy of biology and technology learn from one another? In order to keep these histories
within the purview of the history of biology, we need to decenter heredity from biological
history, a move recently advocated for by Angela Creager, and decenter DNA from its own
history, a move similar to Eden Medina’s recent call to decenter the computer from
histories of computing.16
The approach of commodity histories is particularly attractive for thinking across
biology and technology at once.17 The foundations for commodities histories in biological
science have been well laid in accounts of the creation of research organisms,18 the making
of an international marketplace for biological information,19 histories of various interna-
tional businesses of breeding,20 and of course in histories of biotechnology.21 The notion of
an experimental commodity should be immediately recognisable to historians of science
who have already attended to the commodification of scientific life.22 It should also be
recognisable to contemporary scientists surrounded by commercial flyers, promotional tote
bags, purchase orders, and receipts. It refers to those resources that are more or less vital to
the daily operation of an experimental system, the majority of which are sold by specialist
suppliers, which in biological science have come to include specified lengths of DNA of
various different sizes. But those specialist suppliers did not always exist.
Methodologically this paper is based on a number of resources: oral history interviews
with key figures from throughout the period, some choosing to remain anonymous; the
presentations given at a workshop on the history of DNA synthesis organised between the
Engineering Life project at the University of Edinburgh and the Science History Institute in
Philadelphia; a small amount of archival investigation relating in particular to Applied
Biosystems, Biogen, Celltech, and Vega Biotechnologies; and reviews of literature in
chemistry and biology. The interview quotations have been edited to improve clarity,
and in some cases expanded to include additional information received subsequent to
the interview. The latter occurred on request by the interview subjects when they felt their
original account was unhelpfully limited, but was only agreed to in cases where the
additional information changed little of the tone or context of discussion.
2. Origins of the DNA synthesis knowledge community
The 1950s: in which chemists learn to make DNA in new technical apparatuses
This section walks historians of biology from an area they know well into new conceptual
and analytical territory. My understanding of the origins and emergence of a DNA
synthesis knowledge community is heavily dependent on the historicizing work of actors
themselves and oral history interviews.23 The term ‘knowledge community’ is taken from
HISTORY AND TECHNOLOGY 377
Ann Johnson’s research on the history of engineering.24 Her analysis of how a new
community of technical experts, scientists, and engineers can be grown up around
a particular question or problem, which she dubbs the ‘attractor’, is directly applicable
to the history of DNA synthesis. At the outset some of those most implicated in the
history of synthesising DNA did not think of themselves really as ‘making’ it, and instead
understood their work and its significance in other terms. Over time the larger goal of
synthesising DNA became more nuanced thanks to additional goals, and become more
clearly about making. These additional goals include that its synthesis be accomplished:
more quickly; more reliably; more cheaply; more easily; less wastefully; and so on. By
their nature, these kinds of additional goals required a combination of chemistry and
technology in order for them to be surmounted, and so new technical apparatuses were
designed. Over time the range of actors within the nucleic acids knowledge community
who were prepared to tackle these problems became more sharply defined, and thus an
even smaller professional community of DNA synthesisers emerged, precisely as Johnson
argues for the case of antilock braking systems. This process is begun here and then
further elaborated in Sections 3 and 4, below.
The first chemical synthesis of DNA nucleotides was completed in Cambridge, UK, in
the laboratory of chemist Alexander Todd. Todd presents numerous interesting and
important paths into the history of twentieth century science, linking chemical research
to medicine (particularly through his method for the synthesis of vitamin B1, of con-
siderable value to Hoffman-La Roche), planning and reconstruction during and subse-
quent to the SecondWorldWar, and science in national and imperial projects. He gained
a considerable amount of recognition in his lifetime: awarded a knighthood in 1954;
a Nobel in 1957; becoming Baron Todd of Trumpington in 1962.25 Soraya de
Chadarevian’s history of molecular biology demonstrates that Todd was a consistently
supportive figure for those at the University of Cambridge seeking to increase the
institutional presence of biophysics and eventually molecular biology. We learn that
Todd was asked to give his blessing to Watson and Crick’s model for the structure of
DNA molecules prior to its publication, to avoid potential embarrassment before the
chemical community. And in a long footnote, de Chadarevian also explains that Todd’s
interests in nucleotides helped ensure they were subject to X-ray analysis in the
Cavendish meaning that ‘detailed structural data of the nucleotides were available and
of great use to Watson and Crick while they were working on the structure of DNA’.26
We are now in a position to look well beyond the helix. What really mattered about the
nucleic acid research in Todd’s laboratory was that these chemists were learning how to
make DNA, though Todd himself did not reduce his activities to these terms. Colin
Reese, who joined the Todd lab in 1953 to complete a PhD, explains Todd’s route to
nucleic acid synthesis as follows:
One of Todd’s main aims, which may have developed from his interest in the chemistry of
the B group of vitamins, was the synthesis of the nucleotide coenzymes, and this work was
highlighted in the citation when he received the Nobel Prize for Chemistry in 1957.
However, the scope of the nucleotide research in Todd’s laboratory was very broad indeed
and much fundamental research on nucleoside chemistry and chemical phosphorylation
was carried out in it.27
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So it would be wrong to single DNA out, even amongst the nucleic acids. Rather these were
only some of the molecules of interest, co-enzymes taking precedent due to their offering
amore likely route to therapeutic advance. Nevertheless, the synthesis of DNA amongst these
many other things is central to subsequent developments in the history of biology.
The Todd lab’s synthetic work produced its own characterisation of DNA, which in
the language of chemistry relied on notions of strength and weakness, mild reactivity and
violent reactivity, stability and instability, yield, reaction steps, and so on. His work can
be readily placed within Lily Kay’s international historiography as another investigator of
biological ‘specificity’.28 But better appreciating the distinctiveness of the work of
a synthetic chemist can also trouble any primarily informational view of either the history
of molecular biology or the nature of specificity. We can begin to understand how by
briefly comparing and contrasting Todd’s research with two other chemists equally
invested in the structure and function of DNA at this time, but by other methods and
with different aims. The first, Kurt G. Stern, was at this same time working in the
Department of Chemistry of the Polytechnic Institute in New York.29 There adopting
the assumption that DNA was indeed the material of heredity, alongside a number of
additional constraints regarding how cellular development through such a material
would have to work, he began to derive theories of gene structure. While there is clearly
an informational component to Stern’s perspective, which Kay draws our attention to, it
also matters that he was working out a set of characteristics designed to capture a material
that he had very much at hand (his obituary lists the making of instruments to purify
enzymes and nucleic acids amongst his accomplishments) and, in addition, that his
informational thinking was never removed from a world of material.
If the polynucleotides are formed by the condensation of tetranucleotide units, it is obvious
that each such building block, upon joining up with the chain, has the choice of ‘head to tail’
and ‘tail to tail’. In this manner ‘modulated’ nucleic acid chains incorporating many
different gene codes could be created by the cell.30
While an informational component is clearly present, I want to emphasise that the material
discourse is equally well worth preserving, particularly as people like Todd and Stern were
learning to acquire and manipulate DNA ‘building blocks’ at this time, precisely as organic
chemists and biochemists had already been doing formany other substances for decades.31As
for the informational never being divorced from the material, when Stern turns to explain his
views on how genes must be structured, including photographs of physical models he had
made, he leans on an analogy with technologies for capturing voice recordings, including
photographs of the tracks made into wax surfaces by a recording stylus.32 This, I argue, is
a material imaginary of DNA as much as an informational one.
The second, Erwin Chargaff, is a figure already well known to historians of biology thanks
to his ‘rule’.33 He is important first as a significant member of the early DNA synthesis
knowledge community in his own right, going on to co-edit the 1955 two volume The Nucleic
Acids: Chemistry and Biology, and also for the further support he offers to my decentering of
heredity and emphasis on making.34 Best known for his research determining the ratios of
different nucleosides contained within different samples of DNA, comparing and contrasting
these between species, Chargaff too placed DNA as one group of molecules amongst many.35
Nevertheless, a key aspect of his researchwas concernedwith themaking of quantities ofDNA
nucleosides, achieved by improving methods for enzymatically degrading lengths of DNA
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sourced from organisms. Precisely this kind of research was also underway in the Todd lab at
this time, though with the additional ambition of assembling the degraded nucleosides into
new dinucleotides. In the same way that Todd did not necessarily think of these aims as
learning to make DNA, though he and his staff clearly were doing so, likewise Chargaff was
learning to make the raw materials for DNA synthesis, though his own interests lay in
understanding the spatial arrangement of molecules in the cell. The laboratory life of organic
chemists and biochemists brought them into contact with DNA as a substrate for which they
had particular authority and control. We can cement their inter-relationship with DNA by
further pursuing Chargaff and Todd’s degradation of DNA, which also brings commodities
and key technologies into view.
Nobodyworking on the chemistry of DNA could do sowithout access to rawmaterials. To
complete the work in the paper just cited, Chargaff had to get hold of calf thymus and liver, ox
liver, sheep liver, etc. Todd’s lab meanwhile, in 1952, published their own method for scaling
up the production of nucleosides, one basedonusingherring spermas the initial rawmaterials
from which DNA nucleosides could be extracted. ‘Herring-sperm deoxyribonucleic acid
(180g.; 7.3% of P) of commercial origin (Isaac Spencer and Co. Ltd., Aberdeen) was dissolved
in warm water’. An acknowledgement also went to ‘Messrs. Gea Ltd., Copenhagen, for
a generous gift of deoxyribonuclease’.36 So DNA raw materials and the degrading agent
were by this time already commodities that could be pumped into a laboratory’s experimental
system. The first company mentioned, Isaac Spencer and Co. Ltd., had been founded in the
1880s to manufacture cod liver oils from the fishing trade, but were clearly prepared to
diversify.37 The second was a Danish pharmaceutical manufacturer. One of the current
paper’s largest gaps in knowledge is that I have not been able to track when and where
different suppliers of nucleoside rawmaterials emerged, and how amarket developed.38 I have
however managed to learn how these materials came to be used, how they have changed over
time, and the close relationship between technicalmethods for the extraction of nucleosides or
nucleotides fromorganic sources and their subsequent synthesis. Even in theTodd laboratory,
where processes for making DNA nucleosides and nucleotides through degradation were
being refined and improved, it quickly made more sense for companies to take care of this
work and then sell the nucleosides to laboratory workers. In some cases this was for the
purposes of developingmethods for their synthesis.Wemust also recognise the importance of
column chromatography, which enabled not only the purification of these nucleosides, but
would also go on to form essential technical apparatus for synthesis.
The configurations of biology and chemistry I have just outlined make no sense outside
of a technological repertoire.39 I have been very fortunate to meet the historian Apostolos
Gerontas, who has recently completed the first deep study of the emergence and eventual
development of chromatographic technique.40Chromatography is essentially a method for
the separation of different chemical substances, but as we shall see, it also goes on to serve
a number of other functions. Gerontas shows that though the technique was first developed
by Mikhail Tsvet around the turn of the twentieth century, it was not until the 1930s that it
really began to be taken up widely by organic chemists, who had otherwise remained
committed to chemical methods of separation and degradation.41 Todd himself reflects on
his work’s dependency on these technologies in his Nobel lecture, given in
December 1957.42 Combining the chromatograph with the spectrophotometer – which
measured the capacity for a substance to absorb light – provided the chemist with methods
for getting hold of the material they wanted and also checking that they really did have it.
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This is precisely the kind of work that the Todd lab undertook in their research leading to
the synthesis of DNA. In the process, as I have tried to explain in this first section, DNA
nucleosides and nucleotides were given further characteristics, in this instance by 1) their
rate of diffusion through filtering materials in a chromatographic column, and 2) their
capacity to absorb light. The early DNA synthesis knowledge community was composed of
a broad and heterogeneous group, all invested in DNA synthesis for a wide variety of
reasons. In the next section, as the nucleic acids community grows, so does the ambition to
synthesise become sharper and more competitive, so that Ann Johnson’s process towards
professionalisation gets underway.
3. Successful syntheses: but success by what measure?
The late 1950s and 1960s: In which DNA synthesis increasingly becomes an end in itself
The previous section provided a broader comparative context for the work of the Todd lab,
without actually getting into the successful synthesis of a dinucleotide. This was published in
1955 in paper number 32 of Todd’s nucleotide series, work carried out largely by one of his
laboratory research staff, Adolf Michael Michelson.43 We should note that these researchers
occupied a field effectively identified as belonging to Todd. One’s aim was to be incorporated
as a co-author on a paper inside Todd’s nucleotide series, or the series of papers on
phosphorylation, and so on. The extent to which all of the outputs of the Todd lab are
habitually located in his person is testimony to his effective management of IP-broad priority
claims.44 This circumstance also points to the extent to which the directions and strategies for
research were largely routine, which does not in the least undermine them as difficult or
draining. Systematically altering major and minor features of a reaction, searching for and
trialling different chemicals to act as reagents or blocking agents etc., developing novel
pathways between steps, measuring inputs and outputs, dealing with mistakes and experi-
mental failures, intricate apparatuses, this was the daily work of learning to synthesise DNA.
Which brings us tomotivation. There already existedmethods for themaking ofDNA thatwe
could think of as more biological. ‘Hitherto the synthesis of simple nucleotides by phosphor-
ylation of nucleosides, using other than enzymicmethods, has not been very practicable owing
to the limitations of the methods used’.45 The point, for Todd’s lab, was to create methods for
synthesis that did not rely on enzymatics, which to the organic chemists’mindwas something
like cheating. Or if not cheating, then less worthwhile, because itmissed out on the key pay-off
for the synthetic chemist; that the successful completion of a total synthesis effectively proved
the correctness of your theoretical structure, and kept you from needing difficult-to-attain
starting materials, such as enzymes. Which brings us to evaluation. Todd explains in his
autobiography that he had little to no interest in actually pursuing polynucleotide synthesis
because the nature of the work was too repetitive and boring.46 Michelson was largely left to
his labours, and despite theTodd andMichelson paper becoming a common rallying point for
those building a history of DNA synthesis, the actual method developed, dependent on
phosphotriesters, was initially only of use for making dinucleotides (two base pairs).47
Instead, an altogether different kind of chemical approach gathered momentum, in part
thanks to its immediate capacity to create longer oligonucleotides.
In the mid 1950s, one of Todd’s researchers, George Kenner, went to pursue postdoc-
toral work at the ETH in Zurich in the lab of Vladimir Prelog. There he met and became
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friendly with other postdocs interested in chemical synthesis of biological molecules,
including Har Gobind Khorana. Having convinced Khorana to return with him to
Cambridge to further his protein synthesis chemistry, Khorana ends up becoming inter-
ested there in the nucleotide work being pursued by Todd andMichelson. However, rather
than continue working on phosphotriester chemistry Khorana moves on to develop
a chemistry of his own, based on phosphodiesters, leaving the UK to take up a post at
Vancouver in the Fisheries Research Board of Canada. Using his independent chemical
method, first published in 1956, Khorana found ways to make small trimers of DNA
chemically, which could then be linked up with enzymes.48 It was by this mixed approach
that his lab completed the first synthesis of a whole gene.
In moving towards the later 1950s and early 1960s, in which we find a growth of interest
surrounding Khorana’s alternative phosphodiester approach, our textual sources can begin
to be informedwith participants from oral history interviews, such asMarv Caruthers, Josef
Jiricny and Curt Becker. Caruthers’ contributions to the history of DNA synthesis are
amongst the most well-known, particularly through his co-founding of the company
Applied Biosystems (henceforth, ABI) and development of the phosphoramidite chemistry
at its centre, the latter constituting the third and final chemical strategy for the synthesis of
DNA covered in this paper. Jiricny’s example is no less illuminating, providing as he does
a concrete example of the kind of organic chemist who had begun to be asked tomakeDNA
more routinely for biologists, using the phosphotriester strategies, and who by the end of
the 1970s was looking for ways to professionalise this practice. Becker meanwhile was
a person on the ground at the origins of ABI, playing key roles in the development of their
products, particularly how to best commodify DNA using the phosphoramidite chemistry,
working with Bill Efcavitch of ABI on development of their first commercial synthesier. In
meeting these different transition points, with the fortunes of phosphotriester, phospho-
diester and phosphoramidite methods ebbing and flowing, it is worth being explicit about
the levels of competition surrounding these different chemistries.
Competition between different approaches and strategies is not some extra element of
the history of chemistry but a fundamental feature. All participants and interlocutors
have some kind of view or another about the proper ranking of chemical approaches and
their permutations. Beyond the everyday work of chemists, this competition is also
evidence of the growing specialisation of synthetic chemists within the nucleic acids
research community. What had been the annual Gordon Research Conference on
Proteins and Nucleic Acids, first organised in 1950 (with Kurt Stern as co-chair), became
in 1962 two separate conferences, one on Proteins and the other focussed exclusively on
Nucleic Acids. Around 10 years later the specialist journal Nucleic Acids Research would
be launched. Of course many organic chemists, biologists, biophysicists, and biochemists
would continue to work across the putative divisions, bouncing around different mole-
cules. But a key part of the reason for tracks of specialisation to emerge like this at all, was
that a very real race was on regarding who could synthesize best. While the improvement
of synthesis methods was not the only kind of work underway in these areas, it was
nevertheless the case that improving or suggesting paths towards better synthesis (better
as meaning more reliable, more efficient, easier, faster, higher yielding), was a clear and
attractive way in which to organise one’s lab work and explain the value of one’s results.
The fact of competitiveness between chemical methods therefore forms part of the
historiographical explanation for the eventual professionalisation of DNA synthesis.
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The suggested historiographical argument, that actors picked out efficiencies and dedi-
cated themselves to improvements toward recognised shared goals, will be familiar to
historians of technology and engineering. The critiques these historians have developed
concerning the privileging of efficiencies, the need for engineering to recognise the
politics of its epistemic and design goals, and that technologies do not work determinis-
tically, are likewise necessarily born in mind.49
In addition, I argue that the kind of epistemological programme built up around the
improvement of methods for the synthesis of DNA went on to have another life in biology.
Synthetic chemistry’s epistemic goals and values, which we will soon see integrated into
technologies for biology, came to be broadly embraced by synthetic biology, which most
commonly understands itself to be making biology better, better as meaning more reliable,
more efficient, easier, faster, higher yielding.50 In pursuing a historiographical integration of
biology and technology, I have ended up bringing together elements that matter for the more
specific history of synthetic biology. In this respectmy argument is that synthetic biology locates
and sees itself in its materials. While historians may expect much more evidence for such an
argument than has been supplied here, or can be supplied in a single paper, this is the direction
of argument that my integration of the historiography of biology and technology has takenme.
Khorana’s synthesis of a gene is an excellent place to find further evidence of biology’s debt to
chemistry, and the material-semiotic significance of synthesised DNA for biologists.
Soon after determining his own method for synthesis, Khorana began organising his
lab around a larger project, to synthesise a full gene. Caruthers joined the lab roughly ten
years after Khorana first published his independent synthesis method:
MC: These oligonucleotides were simple ones. Initially the yeast alanine tRNA gene was
proposed to be synthesized using what’s now called PCR, but this was before PCR was
invented by KaryMullis. In other words Khorana actually developed PCR 10-12 years before
Kary Mullis. The way Khorana was originally going to do this synthesis was to prepare two
20mers with 10 base pair overlaps and then carry out repair synthesis which would generate
two 30mers. Then he was going to denature these 30mers, add new 20mers to each end by
hybridization, and extend so as to generate 40mers. Further extensions using this strategy
would generate the tRNA gene. Therefore the total synthesis was predicated upon chemi-
cally synthesizing 20mers.The only enzyme that was required was E. Coli DNA polymerase.
This was the strategy as he explained it to me and was the approach I submitted as
a postdoctoral fellowship grant application for research in his laboratory. As expected,
this grant was funded. However by the time I joined the group as a postdoc, T4 DNA ligase
and kinase had been discovered. As a consequence we were able to synthesize this gene using
12mers, which were easier to prepare. Our total strategy therefore changed. A small section
of the gene was synthesized with 20mers, because that’s how we started, and the rest with
12mers, or in some cases oligomers even less than 12 in length.51
Caruthers also charts an increase in the amount of strategizing between making the first
gene, yeast alanine tRNA, and the second, E.coli tyrosine suppressor tRNA.
MC: That was our strategy for the first gene: Using chemical synthesis followed by initially
DNA polymerase, but later T4 kinase and T4 ligase in order to finish the project. For the
next gene, the E. Coli tyrosine suppressor tRNA gene, we knew much more about how to
strategize our chemical and enzymatic synthesis. For example we knew that the best ligation
strategy was to join oligonucleotides having 5ʹ-pyrimidine to 3ʹ-pyrimidine. Therefore
wherever possible we developed a synthesis plan where an oligonucleotide had pyrimidines
at the 3ʹ and 5ʹ ends. In other words we designed our chemistry mainly to emphasize
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a synthesis strategy that would maximize overall yields and limit various chemical and
enzymatic problems. And we put hard to synthesise nucleotides inside, so we didn’t have to
do so much, so there was a fair amount of planning for the second one. And then on top of
that I got involved, and so did Hans van de Sande, working with a faculty member over in
Chem Engineering on formulating a computer program designed to synthesize genes based
upon everything we had learned during the preparation of the yeast alanine and tyrosine
suppressor genes. This was really a good exercise. We developed a computer program that
would maximise our chemistry. We published that in JACS. I learned a lot about computer
programming when combined with synthesis and how to integrate these two technologies.52
We see how difficult it was to get anything like a 20mer, or even the shorter 12mers they
eventually landed on; the crucial role of enzymatics, the decision to put sequence lengths
that were hard to synthesise ‘inside’, i.e. allow the enzymatics to fill in these sections by
instead synthesising their complementary (and easier to synthesise) oligo; and the
eventual increase in ‘planning’ of synthesis strategies, even resulting in collaboration
with an engineer on a computer programme – DINASYN – to aid in making choices for
sections of synthesis and strategies for their assembly.53 This is not a synthetic biology
project, and to label it as such would be to appreciate it narrowly and anachronistically.
Nevertheless, the key practical and epistemic features that these scientists focus on and
emphasised are some of the very same commonly emphasised in synthetic biology today.
Here I can also take the opportunity to highlight global interest in methods for the
improvement of synthetic DNA at this time.
MC: There were laboratories elsewhere all over the world that were probing how to build
synthetic DNA. These included Alexander Todd, Michael Gait, and Colin Reese in England,
Robert Teoule in France, Wolfgang Pfleiderer, Fritz Eckstein, Hubert Koster, Hartmut
Seliger, Hans Fritz, and Friedrich Cramer in Germany, Kjeld Norris in Denmark, Maciej
Wiewiórowski and Wojciech Stec in Poland, Mikhail Kolosov, Yu Ovchinnikov, and Zoe
Shabarova in Russia, Wang De-Bao andWang Yu in China, Saran Narang, Thomas Nielson,
and Kelvin Ogilvie in Canada, Jacque van Boom in the Netherlands, Tsujiaki Hata, Mario
Ikehara, and Eiko Ohtsuka in Japan, Jacek Smrt in Czechoslovakia, and Robert Letsinger
and Keichi Itakura in the United States. There were a few labs in the US but not too many.54
MC: There was a conference that Hubert Köster hosted at a resort outside Hamburg in 1980.
He literally had everybody in the world who was developing methodologies for DNA and
RNA chemical synthesis at that meeting.55
Attention to this meeting, the 1980 ‘International Symposium on Chemical Synthesis of
Nucleic Acids’ in Hamburg, alongside the annual international Gordon Conference meet-
ings on nucleic acids, would be two of the best ways in which the history of DNA synthesis
could be immediatelymademore global. I have not yet done this work, and it would require
collaboration, but it would be essential to place what I have found so far in proper context.
4. Getting biology hooked on synthesis
The late 1960s, 70s and early 80s: In which chemists bring DNA to biology by diverse
means, machines, and business models
Thus far I have focussed on those for whom synthetic DNA was a central research interest.
But enrolling the average biochemist or biologist would prove to be a job of work.
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MC: They sort of ignored it. Now that’s not a fair statement. Because people were interested
but they couldn’t imagine how they were ever going to use it . . . Arthur Kornberg was very
much interested in what we were doing and often discussed how to use synthetic DNA to
solve biological problems . . . On occasions I have emphasized this observation by telling
a story that happened to me at the 1975 Nucleic Acids Gordon Conference. This conference
was five years prior to the time when we first published our break through research on DNA
synthesis. I was asked to review DNA synthesis . . . that evening I was sitting around a table
having a round of beers with maybe 8 or 10 other scientists you know, and one of them who
is now a member of the US Academy of Sciences, looked at me and he said “Marv, why do
you want to learn how to synthesise DNA?” He said “Khorana used synthetic DNA to solve
the genetic code, and now he’s got his gene, but what else are you going to do with it?” He
said “You’re a bright guy why don’t you go and do something more interesting?” . . . and that
was sort of the general philosophy at the time, kinda “well you know people are going to
dabble making synthetic DNA but what are we ever going to do with it?”
At the origins it was most common for a chemist to take on biological questions themselves,
using synthetic DNA in the process, with biologists coming to be inspired or learn by
example. In this section I show how synthetic DNA, already on its way to becoming
a desirable input for experimenters, finally became an experimental commodity. Different
chemistries, thanks to their features, invited different kinds of embodiment in machinery,
different arrangements of lab personnel, and therefore different kinds of biological research.
While ABI famously won the competition for market dominance, we can situate it amongst
all its competitors by recognising how their 380A DNA synthesis machine, the chemistry it
relied on, and the cost of its reagents, embodied particular lab personnel arrangements and
biological aspirations. We can also better explain the success of their machine as arriving to
supply a commodity that had already been made amenable, desirable, and desired over the
previous 20 or so years, rather than actually launching this desirability itself.
One way in which to develop the historical characterisation of experimental commod-
ities is by attention to the business models that emerged around them. Here the kind of
object that a business model is taken to be is as much an epistemic enterprise as it is
a commercial one.56 The analysis I borrow for these purposes has identified four (and no
more than four) essential business models which, as ideal types, can be used to explore
cases without conflating the actual business with the model it assimilates to.57 The four in
question are: product model; solutions model; matchmaking model; and multi-sided
model. The way in which DNA has been commodified has been diverse, and has changed
over time. In the present paper only the first two, products and solutions, will appear, but
matchmaking and multi-sided DNA synthesis businesses have most certainly emerged in
the period beyond my focus of study. Adopting these categories helps focus my analysis,
but also builds a further much needed path between the history of technology and biology
in business history,58 and outward to histories of capitalism.59
Last, in this section we also reach the key difference between chemists who were DNA
synthesisers, and those who went further, to become part of the professional DNA
synthesis knowledge community. The latter, as Ann Johnson describes, elected to become
embroiled in the process of designing and marketing products, while the former did not.
Of course all chemical investigations still remained crucial for improving existing
methods and searching for new ones, but the additional status of professional, as in
Johnson’s case, makes sense provided we reserve it for that narrower group of people
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getting products to market, and who in the process created a new additional professional
reputation that was going to be risked and tested on new terms.
4.1. Phosphotriester chemistry and the product business model
The fortunes of phosphotriester chemistry had been revived in the mid 1960s thanks to the
intervention of Bob Letsinger, whose lab learnt how to affix the first nucleotide of a sequence
to a solid support, vastly increasing the overall length of polynucloetide which this chemistry
could achieve. Between the mid 1960s and the end of the 1970s phosphotriester chemistry
came to dominate the scene. Decades of familiarity with phosphotriester chemistry, and the
ready availability of the apparatuses and components needed to establish this chemistry in
a single functioning unit on the lab bench, made the path between it and its embodiment in
a bespoke DNA synthesis machine by the end of the 70s relatively straightforward. This area
had also been subject to little commercially significant patenting activity. A search of the
USPTO for ‘phosphotriester’ between 1940 and 1990 does return a few examples from themid
1960s onwards, followed by a larger number from the 1980s onwards, but none give the
appearance of offering a market monopoly on the making and synthesis of triesters.60 This is
no doubt because phosphotriester chemistry always invited too many permutations for any
given approach to provide a straightforward route to patentable, widely applying, and
nonobvious methods, or at least we can conclude that such a patent culture was not success-
fully established in this chemistry. The kinds ofmachine that could be built to incorporate this
chemistry were also small and simple. I interpret these machines as embodying the product
business model, because in a very straightforward sense the consumer was being sold, in
a single transaction, a standardised product designed to fit into their existing working lives. In
these instances DNA was an experimental commodity under your personal and immediate
control, because once you bought themachine the skywas the limit, provided your sky did not
need to extend very far beyond 10-15mers. But the latter was more than enough for certain
applications, particularly if you intended to ligate small oligos into larger polynucleotides.
While not cheap, they were by and large priced within the reach of most labs regularly
synthesising DNA, and could be used with almost any variety of chemistry and reagent.
Following the revival of interest in phosphotriester chemistry, organic chemists
around the world continued attempting to improve it further.61 By the end of the
1970s, some had begun to develop these familiar bench-side rigs into something auto-
matable, packed into a single instrument. Josef Jiricny was one such person, taking
responsibility for the making of DNA for his own research and for nearby biologists.
JJ: I studied chemistry in Birmingham [1970-73] . . . .The reason I studied chemistry is
because I emigrated when I was 18 from Prague, and of course as a refugee there was no
chance of getting into a medical school. So I thought well, chemistry was close enough, but
I realised that I needed some kind of biological angle to what I was doing, so when I finished
my degree in Birmingham I then did a PhD in London [1973-76] . . . When I finished my
PhD I really decided to try and change my direction from synthetic organic chemistry to
something that’s more kind of medically or biologically applied. So I applied for a job with
Colin Reese, who was then the Daniel Professor of Organic Chemistry at King’s College
London in the Strand . . . I was able to work part time on this synthesis of oligonucleotides.62
Here he describes the process of putting together an automated system, photographed in
Image 1.
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I have left the quote as intact as possible, because I know of no other description like it.
JJ: I was offered a postdoc at ICRF [Imperial Cancer Research Fund], in the Chemistry
department. I was then wanting to synthesize a piece of DNA that was modified by some
carcinogen, I wanted to get into cancer research and this had never been done. People treated
mice with carcinogens, and treated cells with carcinogens, but nobody actually knew what
were the exact structures of the adducts in the DNA . . . so I decided to synthesise the whole
Image 1. Josef Jiricny’s automated synthesis machine, using the phosphotriester approach.Pulled
together with various parts from around the Imperial Cancer Research Fund. I am very grateful to Dr.
Jiricny for permission to publish.
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piece of DNA with this modification on it and then find out what the biological consequences
of that modification were . . . I started developing, using Colin Reese’s chemistry, on solid
phase, and it was working reasonably well. So I thought “why not automate it?”, because I was
on the 4th floor in Lincoln’s Inn fields, and there . . . . [were]lots of machines which most of the
time they weren’t using because the first thing they did with them was take them apart and try
to improve them or modify them or whatever. A lot of the time the machines ended up not
working after this little intermezzo. [They] had this old HPLC [High Precision Liquid
Chromatography] which was sort of outdated . . . we were talking over coffee, and I was saying
I would like to see if I can somehow automate the cycle because you essentially had to just write
a very simple programme, you had the coupling reaction which needed to be recycled, joining
the two, to send the compound through the column many times until it reacted. But then you
needed to wash it off, to monitor how good the coupling was, to prepare the column for the
next step and then inject the next nucleotide.63
Key features include: the presence of a chemist using synthetic DNA to answer biological
problems; the ongoing significance of chromatography for the history of making DNA
(here HPLC enabling automation); the overlap and interplay between synthesising one
kind of molecule, amino acids, and another, nucleic acids; the need to begin under-
standing the inner workings of technologies in detail; and the growing interest in
accessing synthetic DNA amongst biochemists and biologists, particularly those working
in fields closely aligned to pharmaceuticals research. We can also glimpse the very widely
and thoroughly established practice amongst synthetic chemists of pursuing experimen-
tal stepwise synthesis of modifications of a molecule of interest, to understand how these
modifications change its properties. Such an experimental strategy is celebrated in central
parts of synthetic biology.64 Though Jiricny was approached by companies interested in
packaging this all into a single machine, this plan never came to fruition, for at precisely
this time ABI’s DNA synthesiser, based on yet another entirely different chemistry, was
released. In the face of its capabilities, Jiricny instead convinced ICRF to purchase one of
these machines with the ambition of becoming manager of ICRF’s DNA synthesis core
facility. Jiricny’s story may not be unique, but it is a concrete example of someone
transitioning from being a chemist who can synthesise DNA, to aspiring to make it
more professionally in bespoke machinery.
Others did make it all the way to packing phosphotriester chemistry into a marketable
DNA synthesis machine. Leon Barstow, President of Vega Biotechnologies, emphasised
how his machine could be considered superior to its competitors, including that of API,
precisely because its phosphotriester chemistry increased an individual user’s control over
their experimental system, including the reagents used and the kinds of chemical approach
applied. In an undated essay, seemingly written during 1981, which was deposited at the
Smithsonian with an example of the Vega machine (originally priced at around $50,000),
Barstow laid out his stall: ‘Until automation, DNA fragments – usually 15 base units in
length – were exceedingly expensive and formed the bottleneck to most bioengineering
development projects. The preparation of a DNA fragment by classical solution methods
could take from 3 to 6 months and cost from $25,000 to $50, 000ʹ.65 This was all now to
change thanks to the availability of machines like his. ‘When I first began designing the
VEGADNA synthesizer in the spring of 1980, I visited most of the academic groups in the
world that were doing research in solid phase DNA synthesis. One of the things I foundwas
that most of the academic groups had their own unique approach and that each group was
changing its approach on an almost weekly basis. Thus, flexibility was essential if the
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machines were to be able to accommodate changes in chemistry as they were introduced’. It
is obviously the case that Barstow’s essay, as with any promotional material, is mainly
serving his interests, and I have not yet found testimonials from clients that could speak to
his machine’s functionality or reliability. But that’s not the point here. Rather it is to capture
aspects of the ways in which DNA became a commodity. In this case, the central features
were user control and customisable chemistry: ‘the phosphotriester method has been
changed more than 30 times in the past two years. On the VEGA machine, all of these
changes were made either through simple keyboard entry or, at worst, through
a straightforward software change . . . The VEGA model 280 DNA synthesizer consists of
a Micro-processor/Controller, a Chemistry unit, and a Printer . . . The technician simply
fills out the form, indicating by alphanumeric codes the solvent or reagent, volume, reaction
time, and disposal port. Once a protocol has been established, it can be stored on a floppy
disk and reused at a future time’. These machines also aspired to give any bench worker
their own device, suitable for self-sufficiency in the design of experiments requiring short
polynucleotides. After all, it could not synthesise many sequences simultaneously.
Of course another way in which to commodify synthetic DNA in the phosphotriester
approach was to reorganise one’s personnel, rather than buy a machine. This is what
Genentech did.
MC: The phosphotriester chemistry was quite labour intensive because people made these
tri-nucleotide blocks. For example for my first trip to Genentech, and I gave a seminar there,
they had these walk in refrigerators filled with all 64 trinucleotide blocks, and then depend-
ing on what you were making chemically, you’d pull this block and this block to make your
6mer. And then this one and this one to make your other 6mer, and then you’d join them
together. So they had technicians whose only job was to make trinucleotides. They had
a group of I’d say 6 or 7 people who were strictly making oligonucleotides.66
Just as the first computers were people, so have our first DNA synthesisers been. In the
next and final examples, we will see how other chemistries and technologies served
alternative ambitions and required different organisations of laboratory personnel.
4.2. Phosphoramidite chemistry and the solutions business model
We have not yet properly introduced the phosphoramidite approach to DNA synthesis. Its
sudden arrival here at the end of my story replicates its arrival into the DNA synthesis
knowledge community. In stark contrast to the phosphotriester approach, it was known by
virtually nobody outside those who developed it into a patented chemical process for the
synthesising of DNA. Indeed the patent ambitions of Marv Caruthers and Serge Beaucage
ensured that the international community was kept in the dark until Caruthers’ lab was
entirely ready. Far from being a chemical system that everyone was familiar with, phos-
phoramidites were forbidding. Those who had tried working with phosphoramidites, such
as Jiricny, had soon given up because the average level of moisture in the lab always
activated the amidites quicker than they could be used in the intended reaction, no matter
how much effort went in to keeping them sealed off (in our interview Jiricny confessed to
thinking that the climates of San Francisco and Los Angeles contributed to Caruthers’
successes, being far less damp than the UK). In terms of commodification, University of
Colorado Boulder was very proactive in defending their IP rights. The Caruthers and
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Beaucage patent, US No. 4415732, effectively covered all phosphoramidite production and
use. Boulder actively pursued litigation against infringers found embedding phosphorami-
dite chemistry into synthesis machines until, as Caruthers explained in our interview, the
costs of litigation eventually reached the same level as the profits from their licenses, at
which point they sold the patents to ABI, who chose to avoid further litigation costs by
freely enabling licenses with interested parties.While this strategy reduced the royalties ABI
received, it also helped to ensure their phosphoramidite chemistry became the international
standard. The fact that there was no pre-existing community of practitioners ready to know
how to adopt the phosphoramidite approach into their working life is the first aspect of this
particular chemistry and technology that pushes it into the solutions category of business
model. The transaction between patent-owning company and the customer meant that
relationships were much more long term, so that customers were not simply buying
a product in a one-off purchase, but were buying into an ongoing consultancy-like
relationship with ABI. The company aimed to keep the machine operating according to
their own designs by, for instance, voiding the warranty on anymachine found to have used
reagents supplied by a company other than ABI. This was not about being master of your
own molecules, but a precision instrument for a precise range of tasks.
The 380A also fits into a solutions business model thanks to the expense of running the
machine. The unit would cost in the region of $42,000 or $55,000 depending on howmany
reaction columns you chose, but really it was the cost of the reagents which ensured it could
only be afforded by elite institutions and pharmaceutical companies (the kinds of organisa-
tions initially prioritised by the ABI sales force). At the outset a single reaction cycle (i.e. the
addition of a single nucleotide) cost in the region of $20-25 in reagent. Indeed in the
original business model, which targeted organic chemists like Jiricny, this was the primary
way in which ABI intended to make profit, through reagent contracts, not the machinery.
Placed inside an institute or company, the 380A was intended to form part of an organisa-
tion’s key facilities unit, a form of centralised organisation of equipment that increasingly
came to be seen as necessary in science subsequent to the Second World War as new more
sophisticated and expensive instruments began to enter the scientific marketplace.67 The
ABI machine was designed to arrive at an institution and start solving the problems of
making DNA for everyone, with implications for personnel: those who had been making it
before (such as the team at Genentech) could be reassigned, or others, as in Jiricny’s case,
could become the provider of synthesised DNA for a whole organisation. Of course, it only
afforded this functionality thanks to its chemical capacity and technological design. Marv
tells the chemistry story as follows:
MC:Mark [Matteucci] joined my lab in 1976. He wanted a PhD in organic chemistry, and so
I thought “you know, nobody has really figured out how to synthetically prepare DNA yet in
a meaningful way”, fast, so people could use it generally . . . once we got the [chloropho-
sphite] chemistry up and running, Mark designed and built with the help of, in the
department we had a person who would repair motors and things like that, and this man
helped him build a little semi-automatic machine, basically on a piece of plywood that we
put together in Chemistry.68
MC: That was the first major breakthrough. The other was with Serge Beaucage who joined
my laboratory as a postdoc. Mark was using 2ʹ-deoxynucleoside chlorophosphites as syn-
thons for preparing DNA. The problem we discovered with these compounds was simple
but difficult to solve. They had to be prepared immediately before use, they were unstable,
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and had to be stored at −70 degrees centigrade. We asked the question “how are we going to
tame these compounds so we can store them in a bottle, keep them for months on
a laboratory shelf, eventually activate them, and BANG they’ll react very quickly?” Serge’s
breakthrough was to develop synthons that would satisfy these criteria. This he accom-
plished by developing synthons we called phosphoramidites.69
MC:When Serge arrived we knewwe had to stabilise these compounds somehow.He had read
the Russian literature, and there was some chemistry there where you could activate amino-
phosphenes by inserting carbon dioxide . . . So we started trying to reproduce that chemistry
and we couldn’t do it . . . But along the way we found we were synthesizing what I was positive
was a dinucleotide, just by that reaction . . . .So we were forming dinucleotides . . . .Serge took
off in that direction and before the summer was out we had phosphoramidite chemistry.70
With regards to founding ABI:
MC: Because of these two breakthroughs, which allowed us to synthesize DNA rapidly and
with a very simple process, I was getting calls almost daily by 1980 from numerous
companies who wanted to collaborate on projects based upon the use of synthetic
DNA . . . the most important development started with a phone call from Winston Salser
in early February 1980. He had been approached by several venture capitalists about forming
a new biotech company and wanted to know if I was interested in participating. Of course
I decided to pursue this opportunity mainly because I was impressed with the quality of the
other scientists who were also involved. After two meetings, at Stanford and UCLA, we
decided to move forward with a new biotech company and leased space in an industrial park
in Thousand Oaks, California. Eventually this company became known as Amgen. Our first
meeting in Thousand Oaks was entirely focused on a discussion of potential projects that
could lead to therapeutic drugs. However Lee Hood and I also proposed that we form
a division that would develop a protein sequencer and DNA synthesizer based upon Lee’s
and my respective research. This was not acceptable to the other scientists who wanted to be
a drug development company. Consequently through separate discussions at this same
meeting, Lee and I decided to proceed with a separate biotech instrument company. As
a result of these discussions, Lee, I, and the venture capitalists, selected an engineer from
Hewlett Packard, Sam Eletr, to form this new instrumentation company which became
known as Applied Biosystems, and we were off and running.71
And the origins of the 380A:
MC:When we decided to start Applied Biosystems, I suggested to Sam Eletr that we hire Bill
Efcavitch and Curt Becker from my laboratory to build the first DNA synthesizer. Bill and
Curt started with a piece of plywood, some tubing, solenoid valves, a tank of nitrogen,
appropriate solvents, and the reagents needed for DNA synthesis. Within a short time, they
were synthesizing DNA on this platform. Consequently Sam hired John Bridger at HP to
fabricate an instrument that we called the 380A DNA Synthesizer. I’d go out there about
once a month, and make suggestions on this and that, but I did not work on that it was Curt
and Bill.72
MC: In those days, scientists who saw the Applied Biosystems protein sequencers and DNA
synthesizers would comment that these machines looked just like an HP product. They had
the same grey-burgundy coloration, the same sleek look and were entirely enclosed in
a smooth frame. I guess this was because they were developed by two former HP engineers-
Sam Eletr and John Bridger. One important comment relates to how rapidly this team
developed these DNA synthesizers. We formed Applied Biosystems in March of 1981. By
December of 1982, about 18 or 19 months later, they were delivering their first commercial
DNA synthesizer to my laboratory.73
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Before the equipment would really take off though, one final problem had to be solved: the
organic chemists. Their commitment to exploring a range of different chemistries, and
reluctance to commit themselves to amachine using only phosphoramidites (becausemany
were really only making DNA for biologists as a side-interest, their primary focus being on
questions in chemistry) kept ABI unsatisfied with sales. Curt Becker, who worked closely
with Bill Efcavitch as he developed the 380A, explains:
CB: There was a handful of organic chemists sprinkled around the world who were
synthesising DNA mostly by triester chemistry. They all had their little twists on it and
they considered their chemistry their chemistry. When we came out with the DNA synthe-
siser we believed . . . the market was those 35, 40, 50 organic chemists around the world that
were synthesising for biologists in their country and around their campuses . . . .They
resisted phosphoramidite chemistry . . . a lot of them tried to reproduce the results that
Marv had published and had been unable to, but you didn’t just make phosphoramidites on
a first time basis and everything was groovy! You had to, it was a painstaking process to put
all of that package together . . . They were “I am not going to go and buy all these expensive
reagents from Applied Biosystems when I can put my own reagents on the instruments”.
I was actually tasked to go to Europe in 1984 and develop processes and cycles to use triester
chemistry on the DNA synthesiser. I came back from that month and a half trip after
interviewing everybody and said “no we’re not going to do that, basically what I think we
should do is bypass the chemists, as a business model they’re not our market segment, we
need to go right directly to the molecular biologists and biologists and sell them the DNA
synthesiser. To be able to do so we’re going to need to be able to cut the cost per-cycle and
we’re going to need to, to compensate for the reduction in cost per-cycle we’re going to
speed up the cycle times, so we’ll give the instrument a higher throughput”.74
In order to make the ABI system now work for biologists rather than chemists, some new
financial and material calculations had to be done. Rather than keeping the costs of
reagents high to continue profiting from small communities of dedicated organic che-
mists, a move that some at ABI advocated for, instead the chemistry of the machine had
to be re-thought to make it now attractive to biologists. A sweet spot needed to be found
where the rapidity of a set of reaction cycles could get a biologist far enough along in their
research programme, that the cost of adopting the machine and its reagents were
preferable to relying on nearby organic chemists who might every now and then have
some time on their hands to make DNA. Finding that sweet spot became far easier for
many biologists around this time, coinciding as it did with the arrival of PCR, for which
one needs a plentiful supply of synthetic DNA, at the very least for the initiation of
amplification. It thereby became both possible and attractive for more biologists to take
on synthesis themselves (in particular thanks to automation), but also pursue different
kinds of biological work.
For instance, the kinds of biological research which really showcased this machine and the
sequencer instruments also sold by ABI, were large gene library searching and synthesising
operations (ideal for ABI for itmeant customers needed to buy both sequencing and synthesis
machines). The best examples of this approach could be found in the pharmaceuticals
industry, and here Caruthers led from the front, for this approach lay behind the speed
which Rasmussen emphasises in the rapid research, development, and sale of erythropoietin
byAmgen, the biotech companyCaruthers had been approached to found by Salser in thefirst
place.75 Located in this equipment, and increasingly serving the biologist directly, DNA was
rendered a rapid, reliable, and mass produced commodity, very much in line with the
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characterisation Michael Fortun develops for the more well-known example of DNA
sequencing.76 However, keeping both sequencing and synthesis in view at the same time
serves to rebalance our historiographical outlook, leaning away from a dominant informa-
tional view, and providing potentially more appropriate terms for a historicizing of synthetic
biology. My account also reminds us of the central role of engineers in the design of these
machines, and how machine-made DNA could accrue some of that profession’s esteem,
particularly whenmultiple thousands of dollars could ride on the decision to buy onemachine
rather than another.
Closely identifying phosphoramidites with the solution business model does not mean
that other chemistries could not also commodify DNA on these terms. I have found one
example of a machine using modified phosphotriester chemistry, one currently on display
at the Science Museum (London), the original creators of which were keen to emphasise
could ‘compete with the rate of synthesis of the phosphite approach’. Again, I am not in
a position to say anything about the truth of these claims, it is simply important that
decades of competition amongst chemists recorded in journals such as Nucleic Acids
Chemistry were now directly impinging on their marketing strategies and also the commo-
dification of DNA as a service to be provided.77Unlike ABI though, Celltech, the company
who built the automatedmachine in question, had no intention of turning their instrument
into a product.78 Rather it was their expertise and capacity in oligonucleotide and gene
design and synthesis that was for sale.
In addition to central research facilities Celltech also offers custom DNA synthesis. In 1983
a separate production unit was set up to provide rapid and reliable supply of oligonucleo-
tides for research customers. To ensure that there is no conflict of interest between ‘in-
house’ and customer needs the unit has separate staff, and its own synthesisers or ‘gene
machines’, designed and built in-house . . . .Longer DNA sequences can also be supplied,
including full length genes produced by automatic synthesis and enzymatic ligation of
oligonucleotides. The strategy for defining the oligonucleotides for synthesis and assembly
into large DNA sequences is computer designed by Celltech. The DNA synthesis service
available to customers extends from oligonucleotides to computer designed gene synthesis
of ligated and cloned genes.79
This kind of business model is one of the most familiar in DNA synthesis today, and
potentially bleeds into the matchmaking business model due to its emphasis on bringing
the right kinds of expertise and interests together at Celltech, though there is no room to
consider these possibilities here.
To recap section 4: I have argued that different formats for the automation of different
chemistries embodied different expectations of biological work, and different ways to
commodify DNA. In the case of Vega, DNA was a small bespoke commodity for the
bench, and the business strategy was to sell small machines to individuals. In the case of
Celltech, DNA design and delivery was a centralised service, the commercial strategy
being to position the company as a one-stop shop for scientific and industrial clients
supplying their DNA needs. Last, for ABI DNA was a commodity that could be rapidly
produced at scale for those able to pay their way into the cutting edge by buying top of the
line equipment and proprietary reagents, capable of multiple syntheses at once. The
decades of improvements to different chemistries, and the more or less stylishly designed
and developed automated equipment that delivered it, leant to any synthesised DNA the
different epistemic and commercial values that produced it.
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5. DNA as experimental commodity
I have explained how DNA came to be made in a variety of ways, how different chemistries
came to be embodied in a range of different apparatuses, each of which produced a different
relationship between DNA’s producers and consumers, resulting in different kinds of
commodification. If I had told this story as primarily a biological one, I would likely have
needed to ignore ormarginalize the significance of the chemico-physical properties of DNA
outside of the cell, and I would have instead ended up exploring synthesised DNA only as
yet another interventionist tool developed in the twentieth century for experimental
biology. But different DNAs produced in different ways have experienced material-
semiotic adventures of their own. I have not attempted to disguise the extent to which
my historical research has been directly inspired by the present and an interest in how
something like synthetic biology could come to be. I have attempted to build a history of
synthesised DNA addressing the material-semiotics of these molecules in a way that is
particularly useful to scientists, social scientists, and philosophers of science in the present,
shining a light on particular meanings and epistemic perspectives which have been present
in synthesised DNA for as long as people have been taking pride in its making. By focussing
on making, my historical approach has not actually needed either Molecular Biology or
Synthetic Biology in order to be written. Actors have come and gone, each carving up the
territory according to their own ambitions and understandings, and the historian is not
required to make a commitment to any of their ontologies or epistemologies. I have used
molecular biology and synthetic biology as recognisable markers, signalling to the reader
where I think this history should be located in the existing historiography, but it does not
actually need such terms in its telling. Demarcation problems have unhelpfully preoccupied
historians, philosophers, and social scientists working in these areas. One can believe that
Molecular Biology as a grand unified international endeavour never happened and that
Synthetic Biology as a grand unified international endeavour isn’t happening, and still
adopt my materials and analysis.
The most straightforward historiographical way in which to ensure the material proper-
ties of DNA were not marginalised by the informational, was to offset the ‘biological’
significances with ‘technological’ ones. Here another potential danger lay, as if I had treated
DNA synthesis and its machines as only another case in the long history of technology,
I would have risked ignoring the multiple (and often biological) significances of this
substrate, and perhaps inadvertently closed down critical exploration of twentieth century
biological science and technology by appearing to passively adopt the perspectives of
central commercial actors. Instead, use of tools and analyses from the history of technology,
and business studies, have kept critical questions open and suggested novel paths for their
future investigation. It is not simply then that this story benefits from dual attention as
biological and technological, but that the integrated historiographical approach achieves
something more than the sum of its parts: a corrective and complementary splinting.
By orienting my study around making molecules, have I done anything particu-
larly novel, or have I simply added one more article to the long and journalistic
tradition of fetishising DNA? In response, I take it that in our time DNA is about as
thoroughly fetishised as it can be, and as a result the process of historical looking
can do a great deal of good, by deflating the phenomenon, making it less dazzling,
and by refocusing our attentions, altering the kinds of questions we are prompted to
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ask in the present, and reevaluating our historiographical priorities. I would also
add that up until now, our histories of molecular biology have far too heavily
emphasised the history of DNA as an information carrying molecule, even as
those same historians have explicitly sought to problematise the reading of DNA
as primarily informational. My research has done the work of grubbying the
informational sacred with the material profane.
Taking this research forward, we would next need to catalogue the variety of ways that
synthesised DNA – and those other molecules which have always been investigated
alongside it – have been used in biological research. For DNA this would include
everything from Jiricny’s carcinogens, to research into its binding, to PCR, to biological
engineering, and outwards to figures such as Nadrian Seeman.80 We could then also
begin incorporating the publics of DNA synthesis, particularly the ways in which science
journalists and communicators have contributed to diverse understandings of DNA
synthesis, its capacities and meanings (see Image 2), and the lives and afterlives of
DNA synthesisers on public display in museums.81
In addition, I have not attempted to gather testimony from the users of any of these
machines, and while it would be dull to pursue such evidence in order to sort out which
Image 2. Left) New Scientist, 29th January 1981, 261. This cartoon accompanies an article on the
‘seamier’ side of DNA synthesis machines, i.e. that some of the commercial players are not to be
trusted and that experience with machines has not always matched expectations. This helps evidence
the kind of world that professional members of the synthesis knowledge community came to occupy.
Right) New Scientist, 23rd May 1985, 22. This cartoon accompanies an article on recent improvements
in synthesis capacity developed in Germany which are explicitly contrasted with the ‘limitations’ of the
ABI machine. The first cartoon to feature DNA synthesis in New Scientist was published 24th October
1963, p. 224 by the cartoonist Bax, whose identity could not be uncovered.
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instruments were best, it would be vastly more interesting to find out what they meant to
people, and how they were interacted with (or not) in any given setting. DNA synthesis
was and remains an important part of the public face of biotechnology, one worth
recovering to be compared and contrasted with genetic recombination at large. The
extent to which DNA synthesis is gendered is also something that should not be over-
looked (though I have done so here), the communities of men here relying on close
relationships for facilitating the fair and proper apportioning of credit, no doubt invol-
ving no small amount of gatekeeping. Engineering and engineers have also entered the
picture. Given the significance of valves and precision liquid handling for the commo-
dification of DNA, which are precisely the same kinds of engineering and components
that matter in Ann Johnson’s history of antilock braking systems, it is possible that these
two histories are really one. But this interesting possibility will have to be pursued
another time. I hope to have provided foundations for a more thorough and global
investigation of DNA synthesis, one exemplifying what can be gained by integrating the
histories of biology and technology.
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